PT  - JOURNAL ARTICLE
AU  - Laura Puentes
AU  - Mehran Makvandi
AU  - Robert Henry Mach
TI  - Molecular Imaging: PARP-1 and Beyond
AID  - 10.2967/jnumed.120.243287
DP  - 2021 Feb 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.120.243287
4099  - http://jnm.snmjournals.org/content/early/2021/02/12/jnumed.120.243287.short
4100  - http://jnm.snmjournals.org/content/early/2021/02/12/jnumed.120.243287.full
AB  - The genetic code to life is balanced on a string of DNA that is under constant metabolic and physical stress from environmental forces. Nearly all diseases have a genetic component caused by or resulting in DNA damage that alters biology to drive pathogenesis. Recent advancements in DNA repair biology have led to the development of imaging tools that target DNA damage response and repair proteins. Positron-emission tomography (PET) has been used for early detection of oncogenic processes and monitoring tumor response to chemotherapeutics that target the DNA repair machinery. In the field of precision medicine, imaging tools provide a unique opportunity for patient stratification by directly measuring drug target expression or monitoring therapy to identify early responders. This overview discusses the state-of-the-art on molecular imaging of DNA damage and repair from the past 5 years, with an emphasis on poly [adenosine diphosphate (ADP) ribose] polymerase-1 (PARP-1) as an imaging target and predictive biomarker of response to therapy.